S.K. Long

428 total citations
28 papers, 381 citations indexed

About

S.K. Long is a scholar working on Cellular and Molecular Neuroscience, Molecular Biology and Pharmacology. According to data from OpenAlex, S.K. Long has authored 28 papers receiving a total of 381 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Cellular and Molecular Neuroscience, 14 papers in Molecular Biology and 5 papers in Pharmacology. Recurrent topics in S.K. Long's work include Neuroscience and Neuropharmacology Research (14 papers), Receptor Mechanisms and Signaling (11 papers) and Neurotransmitter Receptor Influence on Behavior (10 papers). S.K. Long is often cited by papers focused on Neuroscience and Neuropharmacology Research (14 papers), Receptor Mechanisms and Signaling (11 papers) and Neurotransmitter Receptor Influence on Behavior (10 papers). S.K. Long collaborates with scholars based in Netherlands, United Kingdom and United States. S.K. Long's co-authors include Richard H. Evans, Richard J. Siarey, D.A.S. Smith, Chris G. Kruse, Wytse J. Wadman, Taco R. Werkman, Bernard J. Van Vliet, J. Guy Edwards, E.M. Sedgwick and Paul Bevan and has published in prestigious journals such as Neuroscience, British Journal of Pharmacology and European Journal of Pharmacology.

In The Last Decade

S.K. Long

27 papers receiving 366 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S.K. Long Netherlands 11 301 191 109 60 40 28 381
E. Milusheva Bulgaria 11 305 1.0× 216 1.1× 56 0.5× 35 0.6× 26 0.7× 19 488
C. Arlinde Sweden 6 260 0.9× 197 1.0× 67 0.6× 40 0.7× 54 1.4× 8 453
Robert Kerr United Kingdom 11 249 0.8× 145 0.8× 223 2.0× 21 0.3× 29 0.7× 16 397
Katja Hoehn Canada 9 436 1.4× 340 1.8× 117 1.1× 27 0.5× 17 0.4× 11 562
Christophe Lanneau France 12 265 0.9× 236 1.2× 82 0.8× 37 0.6× 30 0.8× 14 515
D A Taylor United States 8 326 1.1× 267 1.4× 118 1.1× 39 0.7× 39 1.0× 16 547
C.A. Doyle United Kingdom 8 250 0.8× 95 0.5× 218 2.0× 26 0.4× 27 0.7× 9 402
F. Vallebuona Italy 10 331 1.1× 205 1.1× 106 1.0× 45 0.8× 56 1.4× 11 457
Bruce Ladenheim United States 9 403 1.3× 161 0.8× 46 0.4× 47 0.8× 105 2.6× 11 542
Hiroo Kuroda Japan 8 270 0.9× 131 0.7× 64 0.6× 31 0.5× 31 0.8× 16 391

Countries citing papers authored by S.K. Long

Since Specialization
Citations

This map shows the geographic impact of S.K. Long's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S.K. Long with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S.K. Long more than expected).

Fields of papers citing papers by S.K. Long

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S.K. Long. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S.K. Long. The network helps show where S.K. Long may publish in the future.

Co-authorship network of co-authors of S.K. Long

This figure shows the co-authorship network connecting the top 25 collaborators of S.K. Long. A scholar is included among the top collaborators of S.K. Long based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S.K. Long. S.K. Long is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hesselink, M.B., et al.. (2003). DU127090: A novel partial dopamine agonist with antipsychotic activity partial agonist character in functional assays in vivo. Schizophrenia Research. 60(1). 117–117. 1 indexed citations
2.
Glennon, Jeffrey, Andrew C. McCreary, Eric Ronken, et al.. (2002). SLV313 is a dopamine D2 receptor antagonist and serotonin 5-HT1A receptor agonist: In vitro and in vivo neuropharmacology. European Neuropsychopharmacology. 12. 277–277. 9 indexed citations
3.
McCreary, Andrew C., Jeffrey Glennon, Arnoud H. J. Herremans, et al.. (2002). SLV313: A novel antipsychotic with additional antidepressant and anxiolytic-like actions. European Neuropsychopharmacology. 12. 274–274. 13 indexed citations
4.
Hesselink, M.B., et al.. (2002). SLV310, a molecule combining potent dopamine D2 receptor antagonism with serotonin reuptake inhibition: in vitro and in vivo neurochemistry. European Neuropsychopharmacology. 12. 319–319. 1 indexed citations
5.
6.
Hesselink, M.B., et al.. (2001). SLV310, a molecule combining potent dopamine D2 receptor antagonism with serotonin reuptake inhibition: In vitro and in vivo neurochemistry. European Neuropsychopharmacology. 11. S252–S252. 2 indexed citations
7.
Herremans, Arnoud H. J., J.A.M. van der Heyden, Andrew C. McCreary, et al.. (2001). SLV310, a molecule combining potent dopamine D2 receptor antagonism with serotonin reuptake inhibition, active in preclinical models for antipsychotic as well as anxiolytic activity. European Neuropsychopharmacology. 11. S251–S251. 4 indexed citations
8.
Long, S.K., et al.. (2000). DU 127090: a highly potent, atypical dopamine receptor ligand — partial agonist character in neurochemistry assays in vivo. European Neuropsychopharmacology. 10. 295–295. 6 indexed citations
9.
Vliet, Bernard J. Van, et al.. (2000). DU 127090: a highly potent, atypical dopamine receptor ligand — high potency but low efficacy at dopamine D2 receptors in vitro. European Neuropsychopharmacology. 10. 294–294. 10 indexed citations
10.
11.
Heyden, J.A.M. van der, et al.. (1996). Flesinoxan: microdialytic profiling of a 5-HT1A receptor agonist. European Neuropsychopharmacology. 6. S4–68. 2 indexed citations
12.
Siarey, Richard J., et al.. (1994). The effects of central myorelaxants on synaptically‐evoked primary afferent depolarization in the immature rat spinal cord in vitro. British Journal of Pharmacology. 111(2). 497–502. 4 indexed citations
13.
Long, S.K.. (1993). Cholecystokinin-induced ventral root depolarization of neonate rat hemicord in vitro. General Pharmacology The Vascular System. 24(1). 171–175. 2 indexed citations
14.
Siarey, Richard J., S.K. Long, & Richard H. Evans. (1992). The effect of centrally acting myorelaxants on NMDA receptor‐mediated synaptic transmission in the immature rat spinal cord in vitro. British Journal of Pharmacology. 107(2). 628–633. 13 indexed citations
15.
Wesselman, Jos P. M., et al.. (1991). The effects of pentobarbital and benzodiazepines on GABA-responses in the periphery and spinal cord in vitro. Neuroscience Letters. 128(2). 261–264. 9 indexed citations
16.
Long, S.K., D.A.S. Smith, Richard J. Siarey, & Richard H. Evans. (1990). Effect of 6‐cyano‐2,3‐dihydroxy‐7‐nitro‐quinoxaline (CNQX) on dorsal root‐, NMDA‐, kainate‐ and quisqualate‐mediated depolarization of rat motoneurones in vitro. British Journal of Pharmacology. 100(4). 850–854. 76 indexed citations
17.
Long, S.K.. (1989). Amino acid pharmacology in a mature rat spinal cord preparation in vitro. Comparative Biochemistry and Physiology Part A Physiology. 93(1). 177–181. 7 indexed citations
18.
Long, S.K., et al.. (1989). Effects of depressant amino acids and antagonists on an in vitro spinal cord preparation from the adult rat. Neuropharmacology. 28(7). 683–688. 13 indexed citations
19.
Evans, Richard H. & S.K. Long. (1989). Primary afferent depolarization in the rat spinal cord is mediated by pathways utilising NMDA and non-NMDA receptors. Neuroscience Letters. 100(1-3). 231–236. 44 indexed citations
20.
Long, S.K., et al.. (1988). An in vitro mature spinal cord preparation from the rat. Neuropharmacology. 27(5). 541–546. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by E. Milusheva Breakdown of academic impact, for papers by C. Arlinde Breakdown of academic impact, for papers by Robert Kerr Breakdown of academic impact, for papers by Katja Hoehn Breakdown of academic impact, for papers by Christophe Lanneau Breakdown of academic impact, for papers by D A Taylor Breakdown of academic impact, for papers by C.A. Doyle Breakdown of academic impact, for papers by F. Vallebuona Breakdown of academic impact, for papers by Bruce Ladenheim Breakdown of academic impact, for papers by Hiroo Kuroda
Rankless by CCL
2026